GNLXGENELUX Corpvs its industry peers
A metric-by-metric comparison of GENELUX Corp against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNLXEsta | $114M#8 | — | 7.1x#11 | 14308.8x#8 | 0.0%#5 | -7.6%#7 | -415175.0%#8 | -199.5%#13 | -424.2%#5 | — | -35.5%#10 | — |
| HURA | $133M#1 | — | 7.2x#12 | — | — | -34.8%#10 | — | -167.6%#12 | -0.1%#1 | — | -16.1%#8 | — |
| BMEA | $129M#2 | — | 10.7x#14 | — | — | 55.4%#4 | — | -509.2%#14 | — | — | -8.7%#6 | — |
| INO | $125M#3 | — | 28.6x#15 | 1914.7x#6 | -70.0%#8 | 20.6%#5 | -132871.3%#6 | -1944.6%#15 | -243.9%#3 | — | -44.4%#12 | — |
| AARD | $122M#4 | — | 1.6x#3 | — | — | -179.7%#14 | — | -77.0%#9 | — | — | -49.3%#13 | — |
| EQ | $120M#5 | — | 2.1x#4 | 2.9x#2 | 13.9%#4 | -177.6%#13 | -57.5%#2 | -40.0%#5 | -368.9%#4 | — | 23.5%#3 | — |
| OKUR | $119M#6 | — | 0.7x#1 | — | — | -13.0%#8 | — | -34.6%#4 | — | — | 21.9%#4 | — |
| PMN | $119M#7 | — | 2.4x#6 | — | — | -1529.3%#16 | — | -80.4%#10 | — | — | 19.9%#5 | — |
| MIST | $114M#9 | — | 6.3x#9 | — | — | -51.9%#12 | — | -0.3%#1 | — | — | -52.7%#14 | — |
| COYA | $111M#10 | — | 2.6x#7 | 14.0x#3 | 123.6%#1 | -42.6%#11 | -283.9%#3 | -49.0%#6 | — | — | -12.2%#7 | — |
| CPIX | $106M#11 | — | 6.1x#8 | 2.4x#1 | 17.6%#3 | 56.2%#3 | -6.3%#1 | -16.3%#3 | — | — | 114.5%#2 | — |
| PLYX | $101M#12 | — | 9.3x#13 | — | — | 70.4%#2 | — | -82.1%#11 | — | — | — | — |
| CTOR | $96M#13 | — | 2.4x#5 | — | — | -17.1%#9 | — | -61.3%#7 | — | — | -43.0%#11 | — |
| ANIX | $95M#14 | — | 6.6x#10 | 454.4x#5 | 0.0%#5 | 13.0%#6 | -5571.9%#5 | -75.5%#8 | -87.0%#2 | — | -18.5%#9 | — |
| RLYB | $89M#15 | 3.4x#1 | 0.9x#2 | 104.0x#4 | 34.9%#2 | 84.5%#1 | -3853.6%#4 | -9.5%#2 | — | — | 265.6%#1 | — |
| NTHI | $87M#16 | — | — | 2185.7x#7 | -51.8%#7 | -422.3%#15 | -145637.5%#7 | — | — | — | -68.2%#15 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice